# treatment resistant depression FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/treatment-resistant-depression

> No upcoming FDA catalysts in treatment resistant depression; 4 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for treatment resistant depression?

No upcoming FDA catalysts in treatment resistant depression; 4 past events are recorded. Press release filed with the SEC (EX-99): "Alto's most advanced and differentiated program, ALTO-207, remains on track to initiate a Phase 2b clinical trial in the first half of 2026." [Calendar and source filings](https://sec-api.dev/indications/treatment-resistant-depression)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-038593, https://www.sec.gov/Archives/edgar/data/1999480/000110465926038593/tm2610746d1_ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-04-01. Cite: https://sec-api.dev/indications/treatment-resistant-depression#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Q2 2025 | [COMP005 topline data readout](https://sec-api.dev/pdufa/comp005) | CMPS | treatment resistant depression | scheduled | "We are nearing completion of enrollment in our first pivotal study in TRD, COMP005, and expect to report top-line 6-week data in the second quarter of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1816590/000162828025008412/cmps-20241231.htm)) |
| May 28, 2025 | [Psilocybin primary completion](https://sec-api.dev/pdufa/psilocybin) | CMPS | Treatment Resistant Depression | completed | "NCT05624268 (Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-28 (ACTUAL); Lead Sponsor COMPASS Pathways." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05624268)) |
| November 13, 2025 | [Psilocybin primary completion](https://sec-api.dev/pdufa/psilocybin) | CMPS | Treatment Resistant Depression | completed | "NCT05711940 (Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-11-13 (ACTUAL); Lead Sponsor COMPASS Pathways." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05711940)) |
| 1H 2026 | [ALTO-207 trial start](https://sec-api.dev/pdufa/alto-207) | ANRO | treatment resistant depression | scheduled | "Alto's most advanced and differentiated program, ALTO-207, remains on track to initiate a Phase 2b clinical trial in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000110465926038593/tm2610746d1_ex99-1.htm)) |

## Drugs

- [COMP005](https://sec-api.dev/pdufa/comp005) (CMPS)
- [Psilocybin](https://sec-api.dev/pdufa/psilocybin) (CMPS)
- [ALTO-207](https://sec-api.dev/pdufa/alto-207) (ANRO)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/treatment-resistant-depression.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "treatment resistant depression FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/treatment-resistant-depression

```bibtex
@misc{secapidev_indications_treatment_resistant_depression_20261116,
  title        = {treatment resistant depression FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/treatment-resistant-depression}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_treatment_resistant_depression_20261116","title":"treatment resistant depression FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/treatment-resistant-depression","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
